From CNBC:

Novo Nordisk outperformed with 2023 earnings, driven by soaring sales of its anti-obesity and diabetes drugs. Sales rose to 232.3 billion kroner, with an operating profit of 102.6 billion kroner. Valuation reached $506 billion. Strong demand for anti-obesity drug Wegovy caused 154% spike, while expanding supply chain investment to keep pace with need. CEO Lars Fruergaard Jørgensen expects continued high demand for company’s products. Competition in the weight loss market has brought lower prices, but Novo Nordisk still anticipates high demand.



Read more: Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic